Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era

International Journal of STD and AIDS

Volumn 25, Issue 14, 2014, Pages 1022-1028

  Munier, Anne Lise ^a   de Lastours, Victoire ^a   Porcher, Raphaël ^a   Donay, Jean Luc ^a   Pons, Jean Louis ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

AIDS; HIV; opportunistic infections; pneumococcal disease; risk factors; Streptococcus pneumoniae

Indexed keywords

VIRUS RNA; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CHARLSON COMORBIDITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; VIRUS REPLICATION; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VIRAL LOAD;

EID: 84921503116     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462414528316     Document Type: Article

References (26)

1. Redd SC,Rutherford GW,Sande MA, et al.The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.J Infect Dis. 1990;162:1012-1017
2. Grau I,Pallares R,Tubau F, et al.Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.Arch Intern Med. 2005;165:1533-1540
3. Heffernan RT,Barrett NL,Gallagher KM, et al.Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000.J Infect Dis. 2005;191:2038-2045
4. Jordano Q,Falcó V,Almirante B, et al.Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.Clin Infect Dis. 2004;38:1623-1628
5. Yin Z,Rice BD,Waight P, et al.Invasive pneumococcal disease among HIV-positive individuals, 2000–2009.AIDS. 2012;26:87-94
6. Hicks LA,Harrison LH,Flannery B, et al.Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004.J Infect Dis. 2007;196:1346-1354
7. McEllistrem MC,Mendelsohn AB,Pass MA, et al.Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection.J Infect Dis. 2002;185:1364-1368
8. Frankel RE,Virata M,Hardalo C, et al.Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.Clin Infect Dis. 1996;23:577-584
9. Kyaw MH,Rose CE,Fry AM, et al.The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults.J Infect Dis. 2005;192:377-386
10. Dworkin MS,Ward JW,Hanson DL, et al.Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.Clin Infect Dis. 2001;32:794-800
11. Barry PM,Zetola N,Keruly JC, et al.Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003.AIDS. 2006;20:437-444
12. Peñaranda M,Falco V,Payeras A, et al.Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.Clin Infect Dis. 2007;45:e82-e87
13. Gebo KA,Moore RD,Keruly JC, et al.Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients.J Infect Dis. 1996;173:857-862
14. Everett DB,Mukaka M,Denis B, et al.Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi.PLoS ONE. 2011;6:e17765-e17765
15. De Groot V,Beckerman H,Lankhorst GJ, et al.How to measure comorbidity. a critical review of available methods.J Clin Epidemiol. 2003;56:221-229
16. Zavascki AP,Fuchs SC.The need for reappraisal of AIDS score weight of Charlson comorbidity index.J Clin Epidemiol. 2007;60:867-868
17. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
18. Anderson KB,Guest JL,Rimland D.Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.Clin Infect Dis. 2004;39:1507-1513
19. Bedimo RJ,McGinnis KA,Dunlap M, et al.Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.J Acquir Immune Defic Syndr. 2009;52:203-208
20. Bennett NM,Buffington J,LaForce FM.Pneumococcal bacteremia in Monroe County, New York.Am J Public Health. 1992;82:1513-1516
21. French N,Gordon SB,Mwalukomo T, et al.A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults.N Engl J Med. 2010;362:812-822
22. Klugman KP,Madhi SA,Huebner RE, et al.A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.N Engl J Med. 2003;349:1341-1348
23. Janoff EN,Fasching C,Ojoo JC, et al.Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine.J Infect Dis. 1997;175:975-978
24. French N,Moore M,Haikala R, et al.A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.J Infect Dis. 2004;190:707-712
25. Pedersen RH,Lohse N,Østergaard L, et al.The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.HIV Med. 2011;12:323-333
26. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Morb Mortal Wkly Rep. 2012;61:816-819